Chemotherapy Resistance and Sensitivity Testing in Lung Tumors

Study summary

The purpose of this study is to screen chemotherapy drugs currently used to treat lung cancer and determine the most effective treatment based on results of chemo sensitivity testing on the patients own cancer cells in the laboratory. The results of this screening will not influence the patients treatment.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forLung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 27, 2016 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Marshall University

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: Marshall University
Interventions being studied: Not specified

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

suspected or confirmed diagnosis of lung cancer
undergoing a fine needle aspiration, core biopsy, or excisional biopsy for diagnosis.
Chemotherapy must be clinically indicated for treatment of the patient's qualifying disease
Patient must be at least 18 years of age
Patient must have signed an IRB approved informed consent form for the data collection study prior to entry of data into the enrollment form in the database.

Reasons someone may not be able to joinExclusion criteria

Patient pathology shows benign pathology for sample submitted
Patient is not indicated to receive chemotherapy for their disease

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Cabell Huntington HospitalHuntington, West Virginia

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 27, 2016. Always confirm current availability with the study team.

View original record ↗